Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$21.02 USD

21.02
766,481

-0.22 (-1.04%)

Updated Oct 21, 2024 04:00 PM ET

After-Market: $21.02 0.00 (0.00%) 4:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

by Zacks Equity Research

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

by Kanishka Das

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder

by Zacks Equity Research

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.

Catalyst Pharmaceutical (CPRX) Q4 Earnings Lag Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is AmerisourceBergen (ABC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AmerisourceBergen (ABC) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?

by Zacks Equity Research

Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).

Allogene's (ALLO) CAR T Therapy Gets Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Allogene's (ALLO) early-stage CAR T therapy candidate, ALLO-316, for treating advanced or metastatic clear cell RCC.

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

by Zacks Equity Research

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) Q4 Earnings Lag Estimates

by Zacks Equity Research

Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study

by Zacks Equity Research

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales

by Zacks Equity Research

Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics

by Zacks Equity Research

Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.

JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs

by Zacks Equity Research

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Kinjel Shah headshot

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

by Kinjel Shah

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.

Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"

by Zacks Equity Research

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

by Zacks Equity Research

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.